CytomX Therapeutics Inc’s recently made public that its Chief Business Officer Landau Jeffrey B unloaded Company’s shares for reported $5139.0 on Aug 20 ’24. In the deal valued at $1.23 per share,4,181 shares were sold. As a result of this transaction, Landau Jeffrey B now holds 119,056 shares worth roughly $-0.13 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, BELVIN MARCIA sold 4,181 shares, generating $5,139 in total proceeds. Upon selling the shares at $1.23, the SVP, Chief Scientific Officer now owns 175,648 shares.
Before that, ROWLAND LLOYD A sold 4,181 shares. CytomX Therapeutics Inc shares valued at $5,139 were divested by the General Counsel at a price of $1.23 per share. As a result of the transaction, ROWLAND LLOYD A now holds 130,797 shares, worth roughly $0.14 million.
Piper Sandler upgraded its CytomX Therapeutics Inc [CTMX] rating to an Overweight from a a Neutral in a research note published on May 28, 2024; the price target was increased to $3.50 from $2.25. A number of analysts have revised their coverage, including Wedbush’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “an Outperform”. Jefferies also remained covering CTMX and has increased its forecast on May 06, 2024 with a “Buy” recommendation from previously “Hold” rating. JP Morgan revised its rating on April 22, 2024. It rated CTMX as “a Neutral” which previously was an “an Underweight”.
Price Performance Review of CTMX
On Monday, CytomX Therapeutics Inc [NASDAQ:CTMX] saw its stock fall -5.22% to $1.09. Over the last five days, the stock has lost -6.84%. CytomX Therapeutics Inc shares have fallen nearly -29.68% since the year began. Nevertheless, the stocks have fallen -9.17% over the past one year. While a 52-week high of $5.85 was reached on 05/01/24, a 52-week low of $1.04 was recorded on 10/14/24. SMA at 50 days reached $1.1906, while 200 days put it at $1.6688.
Levels Of Support And Resistance For CTMX Stock
The 24-hour chart illustrates a support level at 1.0633, which if violated will result in even more drops to 1.0367. On the upside, there is a resistance level at 1.1433. A further resistance level may holdings at 1.1967. The Relative Strength Index (RSI) on the 14-day chart is 38.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0336, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 100.00%. Stochastics %K at 22.62% indicates the stock is a holding.
How much short interest is there in CytomX Therapeutics Inc?
A steep rise in short interest was recorded in CytomX Therapeutics Inc stocks on 2024-09-30, dropping by -0.9 million shares to a total of 6.25 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 7.15 million shares. There was a decline of -14.35%, which implies that there is a negative sentiment for the stock.
